Barclays PLC Boosts Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Barclays PLC lifted its position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 311.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 211,300 shares of the company’s stock after buying an additional 159,924 shares during the quarter. Barclays PLC owned approximately 0.10% of Lineage Cell Therapeutics worth $192,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in Lineage Cell Therapeutics by 35.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock worth $435,000 after purchasing an additional 114,762 shares during the period. Rhumbline Advisers increased its holdings in Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after purchasing an additional 17,411 shares during the period. Renaissance Technologies LLC increased its holdings in Lineage Cell Therapeutics by 10.0% during the 2nd quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock worth $582,000 after purchasing an additional 53,022 shares during the period. XTX Topco Ltd purchased a new stake in Lineage Cell Therapeutics during the 2nd quarter worth about $61,000. Finally, Raffles Associates LP increased its holdings in Lineage Cell Therapeutics by 35.8% during the 2nd quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock worth $4,346,000 after purchasing an additional 1,147,800 shares during the period. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN:LCTX opened at $0.59 on Wednesday. The firm has a market cap of $129.70 million, a price-to-earnings ratio of -4.90 and a beta of 1.18. Lineage Cell Therapeutics, Inc. has a one year low of $0.48 and a one year high of $1.61.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on LCTX shares. HC Wainwright upped their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a research report on Friday, January 3rd. Finally, Maxim Group decreased their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $4.80.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.